

Sanford Health South Region Antibigram

Gram Negative Organisms

2026 Antibigram (Jan-Dec 2025 data)	<i>Acinetobacter baumannii</i> complex	<i>Citrobacter freundii</i> complex	<i>Enterobacter cloacae</i> complex	<i>Enterobacter cloacae</i> complex, CRE	<i>Escherichia coli</i>	<i>Escherichia coli</i> , ESBL	<i>Klebsiella aerogenes</i>	<i>Klebsiella oxytoca</i>	<i>Klebsiella pneumoniae</i>	<i>Klebsiella pneumoniae</i> , ESBL	<i>Proteus mirabilis</i>	<i>Proteus mirabilis</i> , ESBL	<i>Serratia marcescens</i>	<i>Salmonella</i> species	<i>Shigella</i> species	<i>Pseudomonas aeruginosa</i>	<i>Pseudomonas aeruginosa</i> , CRPA	<i>Stenotrophomonas maltophilia</i>	<i>Haemophilus influenzae</i>	
	Isolates (N)	54 ^a	448	489	55	10984	656	305	368	1830	104	848	27 ^c	114	62 ^b	31 ^b	964	70	67	49 ^b
Antibiotic	Susceptible (%)																			
Ampicillin	R	R	R	R	62	*	R	R	R	R	79	*	R	88	3	R	R	R	R	67
Ampicillin/ Sulbactam	98	R	R	R	66	*	R	68	81	*	81	*	R	-	-	R	R	R	R	-
Amoxicillin/ Clavulanate	R	R	R	R	87	*	R	91	94	*	100	*	R	-	-	R	R	R	R	-
Piperacillin/ Tazobactam	72	87	70	R	96	*	75	91	94	*	100	*	93	-	-	93	74	R	R	-
Cefazolin (not uUTI) ^d	R	R	R	R	70	*	R	-	84	*	10	*	R	R	R	R	R	R	R	-
Cefazolin (uUTI) ^{d,e}	R	R	R	R	92	*	R	-	93	*	94	*	R	R	R	R	R	R	R	-
Ceftazidime	76	-	-	-	-	-	-	-	-	-	-	-	-	-	-	98	82	-	-	-
Ceftriaxone	-	-	-	-	93	*	-	92	94	*	96	*	-	90	91 ^c	R	R	R	R	100
Cefepime	78	100	94	76	95	*	99	98	96	*	97	*	100	-	-	97	82	-	-	-
Aztreonam	R	-	-	-	-	-	-	-	-	-	-	-	-	-	-	83	58	R	R	-
Ertapenem	R	100	88	0	100	100	96	100	98	100	100	100	97	-	-	R	R	R	R	-
Meropenem	-	100	100	100	100	100	100	100	100	100	100	-	100	100	-	93	0	R	R	100
Ciprofloxacin	87	95	95	92	81	17	96	98	90	24	76	25	91	80	64	89	60	-	-	-
Levofloxacin	93	95	94	87	81	17	95	98	89	18	76	25	91	-	-	83	47	86	86	-
Amikacin	-	100	100	-	99	99	99	100	100	98	100	-	100	R	R	100	100	R	R	-
Gentamicin	94	99	99	98	93	75	100	98	98	69	91	40	97	R	R	R	R	R	R	-
Tobramycin	96	99	99	98	93	71	100	98	97	58	92	34	90	R	R	98	93	R	R	-
Trimethoprim/ Sulfamethoxazole	89	96	96	96	85	49	100	97	92	23	82	18	97	93	67	R	R	R	83	-
Nitrofurantoin ^e	-	90	36	30	97	91	12	75	22	12	R	R	R	R	-	R	R	-	-	-

a) Results from 2024-2025

b) Results from 2023-2025

c) < 30 isolates or subset of total isolates; results may not be statistically significant

d) uUTI = uncomplicated urinary tract infection

e) urine only

-) not tested, not reported, or insufficient data

*) reported as resistant for ESBL; treatment not recommended

R) intrinsically resistant or clinically ineffective; treatment not recommended

% susceptible ≥ 90

% susceptible 80-89

% susceptible 60-79

% susceptible < 60 or R

Traffic light color palette

Sanford Health South Region Antibigram

Gram Negative Organisms

2026 Antibigram (Jan-Dec 2025 data)	<i>Acinetobacter baumannii</i> complex	<i>Citrobacter freundii</i> complex	<i>Enterobacter cloacae</i> complex	<i>Enterobacter cloacae</i> complex, CRE	<i>Escherichia coli</i>	<i>Escherichia coli</i> , ESBL	<i>Klebsiella aerogenes</i>	<i>Klebsiella oxytoca</i>	<i>Klebsiella pneumoniae</i>	<i>Klebsiella pneumoniae</i> , ESBL	<i>Proteus mirabilis</i>	<i>Proteus mirabilis</i> , ESBL	<i>Serratia marcescens</i>	<i>Salmonella</i> species	<i>Shigella</i> species	<i>Pseudomonas aeruginosa</i>	<i>Pseudomonas aeruginosa</i> , CRPA	<i>Stenotrophomonas maltophilia</i>	<i>Haemophilus influenzae</i>	
	Isolates (N)	54 ^a	448	489	55	10984	656	305	368	1830	104	848	27 ^c	114	62 ^b	31 ^b	964	70	67	49 ^b
Antibiotic	Susceptible (%)																			
Ampicillin	R	R	R	R	62	*	R	R	R	R	79	*	R	88	3	R	R	R	R	67
Ampicillin/ Sulbactam	98	R	R	R	66	*	R	68	81	*	81	*	R	-	-	R	R	R	R	-
Amoxicillin/ Clavulanate	R	R	R	R	87	*	R	91	94	*	100	*	R	-	-	R	R	R	R	-
Piperacillin/ Tazobactam	72	87	70	R	96	*	75	91	94	*	100	*	93	-	-	93	74	R	R	-
Cefazolin (not uUTI) ^d	R	R	R	R	70	*	R	-	84	*	10	*	R	R	R	R	R	R	R	-
Cefazolin (uUTI) ^{d,e}	R	R	R	R	92	*	R	-	93	*	94	*	R	R	R	R	R	R	R	-
Ceftazidime	76	-	-	-	-	-	-	-	-	-	-	-	-	-	-	98	82	-	-	-
Ceftriaxone	-	-	-	-	93	*	-	92	94	*	96	*	-	90	91 ^c	R	R	R	R	100
Cefepime	78	100	94	76	95	*	99	98	96	*	97	*	100	-	-	97	82	-	-	-
Aztreonam	R	-	-	-	-	-	-	-	-	-	-	-	-	-	-	83	58	R	R	-
Ertapenem	R	100	88	0	100	100	96	100	98	100	100	100	97	-	-	R	R	R	R	-
Meropenem	-	100	100	100	100	100	100	100	100	100	100	-	100	100	-	93	0	R	R	100
Ciprofloxacin	87	95	95	92	81	17	96	98	90	24	76	25	91	80	64	89	60	-	-	-
Levofloxacin	93	95	94	87	81	17	95	98	89	18	76	25	91	-	-	83	47	86	-	-
Amikacin	-	100	100	-	99	99	99	100	100	98	100	-	100	R	R	100	100	R	R	-
Gentamicin	94	99	99	98	93	75	100	98	98	69	91	40	97	R	R	R	R	R	R	-
Tobramycin	96	99	99	98	93	71	100	98	97	58	92	34	90	R	R	98	93	R	R	-
Trimethoprim/ Sulfamethoxazole	89	96	96	96	85	49	100	97	92	23	82	18	97	93	67	R	R	R	R	83
Nitrofurantoin ^e	-	90	36	30	97	91	12	75	22	12	R	R	R	-	-	R	R	-	-	-

a) Results from 2024-2025

b) Results from 2023-2025

c) < 30 isolates or subset of total isolates; results may not be statistically significant

d) uUTI = uncomplicated urinary tract infection

e) urine only

-) not tested, not reported, or insufficient data

*) reported as resistant for ESBL; treatment not recommended

R) intrinsically resistant or clinically ineffective; treatment not recommended

% susceptible ≥ 90

% susceptible 80-89

% susceptible 60-79

% susceptible < 60 or R

Alternative color palette